Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease-MedSci.cn

Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease

Yoneda, M; Kobayashi, T; Asako, N; Iwaki, M; Saito, S; Nakajima, A

Yoneda, M (通讯作者)，Yokohama City Univ Med, Dept Gastroenterol & Hepatol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa, Japan.

HEPATOBILIARY SURGERY AND NUTRITION, 2022; 11 (3): 433

科室
- - 订阅+
  - 更多科室
工具
服务